BridgeBio Issues Convertible Senior Notes Due 2033

Details

issued $632.5 million aggregate principal amount of 0.75% Convertible Senior Notes due 2033 in a private offering to qualified institutional buyers. The notes are convertible into cash, shares of BridgeBio's common stock, or a combination thereof. BridgeBio intends to use the net proceeds from the offering to repurchase, settle future conversion obligations in respect of, or repay at maturity a portion of its 2.50% Convertible Senior Notes due 2027 and for general corporate purposes, which may include working capital, capital expenditures, and/or debt repayment. The company also used $82.5 million of cash on hand to repurchase 1,081,825 shares of its common stock concurrently with the closing of the Note Offering from certain purchasers of the notes. The notes and any shares of common stock issuable upon conversion of the notes have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or applicable exemption from registration requirements.

Items reported

About BridgeBio Pharma Inc.

BridgeBio Pharma Inc. is a cutting-edge biotechnology company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases. The company's primary purpose is to bridge the gap in medical research and bring breakthrough therapies to those with rare and often overlooked genetic disorders. By utilizing a targeted approach, BridgeBio Pharma Inc. works across multiple sectors including dermatology, oncology, cardiology, neurology, and endocrinology. The company partners with academic institutions, research organizations, and industry leaders to harness the latest scientific advancements in genomics and biotechnology. Established with a mission to translate genetic research into real-world medical solutions, BridgeBio Pharma Inc. plays a significant role in the biopharmaceutical market. It is heavily involved in the early and late stages of drug development, positioning itself as a key player in the quest to address unmet medical needs. This focus on genetic-centric therapies underlines its importance in the rapidly evolving landscape of biotechnology and personalized medicine.